跳至主要内容
临床试验/NL-OMON46873
NL-OMON46873
招募中
不适用

euronal correlates of post-stroke epilepsy and the associated cognitive impairment - PoSECI-7T

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 72 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
Medisch Universitair Ziekenhuis Maastricht
入组人数
72
状态
招募中
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Observational invasive

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

入排标准

入选标准

  • \- Patients suffering from stroke (and post\-stroke epilepsy), including both brain infarction, cerebral hemorrhage and clinically significant hemorrhagic transformation of stroke (or a primary intracerebral hemorrhage)
  • \- Patients suffering from post\-stroke epilepsy after cortical stroke defined as one or more unprovoked epileptic seizures occurring more than one week after the stroke, according to International League Against Epilepsy criteria.
  • \- Patients suffering from cortical stroke, with the onset of acute stroke symptoms more than 4 months prior to inclusion.
  • \- Age \> 18 years

排除标准

  • \-onset of stroke (and epilepsy for post\-stroke epilepsy patients) less than 4 months ago
  • \-In case of the PSE group: onset of epilepsy within a week or 2 years after the onset of stroke.
  • \-previous history of epilepsy
  • \-history of another cerebral disorder (neurodegenerative diseases, tumours)
  • \-inability to provide informed consent
  • \- any contraindication for MRI: metallic foreign body, pacemaker, claustrophobia, pregnancy, tattoos, permanent make\-up.
  • \- known contrast allergy to gadolinium, insufficient kidney function (eGFR\<\=30\).
  • \- A history of topiramate use as an anti\-epileptic drug, because of its known cognitive effects.

结局指标

主要结局

未指定

相似试验